ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1513
CHEMBL1513
Compound Name IRBESARTAN
ChEMBL Synonyms IRBESARTAN | BMS-186295 | IFIRMASTA | APROVEL | AVAPRO | SABERVEL | KARVEA | SR 47436
Max Phase 4 (Approved)
Trade Names AVAPRO | KARVEA | APROVEL | IFIRMASTA | IRBESARTAN | SABERVEL
Molecular Formula C25H28N6O

Additional synonyms for CHEMBL1513 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)c4ccccc4c5nn[nH]n5
Standard InChI InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31( ...
Download InChI
Standard InChI Key YOSHYTLCDANDAN-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Curated Drug Pharmacokinetic Data
  • DrugMatrix
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1513

Molecule Features

CHEMBL1513 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Type-1 angiotensin II receptor antagonist Type-1 angiotensin II receptor FDA

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Ehlers-Danlos SyndromeD004535Orphanet:286Ehlers-Danlos syndrome, vascular type3ClinicalTrials
Renal Insufficiency, ChronicD051436EFO:0003884chronic kidney disease3ClinicalTrials
HypercholesterolemiaD006937HP:0003124hypercholesterolemia3ClinicalTrials
Cardiovascular DiseasesD002318EFO:0000319cardiovascular disease4ATC
Diabetic NephropathiesD003928EFO:0000401diabetic nephropathy0ClinicalTrials
SepsisD018805HP:0100806sepsis3ClinicalTrials
Heart FailureD006333EFO:0000373congestive heart failure3ClinicalTrials
Atrial FibrillationD001281EFO:0000275atrial fibrillation3ClinicalTrials
Glomerulonephritis, IGAD005922EFO:0004194IGA glomerulonephritis3ClinicalTrials
Glomerulosclerosis, Focal SegmentalD005923EFO:0004236focal segmental glomerulosclerosis2ClinicalTrials
Hemorrhagic Fever, EbolaD019142EFO:0007243Ebola hemorrhagic fever1ClinicalTrials
Hepatitis C, ChronicD019698EFO:0004220Chronic Hepatitis C infection3ClinicalTrials
HypertensionD006973EFO:0000537hypertension4ClinicalTrials
DailyMed
Marfan SyndromeD008382Orphanet:558Marfan syndrome2ClinicalTrials

Clinical Data

ClinicalTrials.gov IRBESARTAN
The Cochrane Collaboration IRBESARTAN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1513. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL227 Type-1 angiotensin II receptor Homo sapiens 1.000
CHEMBL263 Type-1B angiotensin II receptor Rattus norvegicus 1.000
CHEMBL4607 Angiotensin II type 2 (AT-2) receptor Homo sapiens 1.000
CHEMBL3374 Angiotensin II type 1a (AT-1a) receptor Bos taurus 1.000
CHEMBL3948 Angiotensin II type 1a (AT-1a) receptor Oryctolagus cuniculus 1.000
CHEMBL329 Type-1A angiotensin II receptor Rattus norvegicus 1.000
CHEMBL1671613 Type-1 angiotensin II receptor Cavia porcellus 1.000
CHEMBL257 Angiotensin II type 2 (AT-2) receptor Rattus norvegicus 1.000



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL227 Type-1 angiotensin II receptor Homo sapiens 1.000
CHEMBL263 Type-1B angiotensin II receptor Rattus norvegicus 1.000
CHEMBL4607 Angiotensin II type 2 (AT-2) receptor Homo sapiens 1.000
CHEMBL3374 Angiotensin II type 1a (AT-1a) receptor Bos taurus 1.000
CHEMBL3948 Angiotensin II type 1a (AT-1a) receptor Oryctolagus cuniculus 1.000
CHEMBL329 Type-1A angiotensin II receptor Rattus norvegicus 1.000
CHEMBL1671613 Type-1 angiotensin II receptor Cavia porcellus 1.000
CHEMBL257 Angiotensin II type 2 (AT-2) receptor Rattus norvegicus 1.000

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
428.5 428.2325 4.78 7 87.13 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
5 1 0 7 1 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
4.24 2.52 6.15 4.19 3 32 0.59

Structural Alerts

There are no structural alerts for CHEMBL1513

Compound Cross References

ATC C - CARDIOVASCULAR SYSTEM
C09 - AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09C - ANGIOTENSIN II ANTAGONISTS, PLAIN
C09CA - Angiotensin II antagonists, plain
C09CA04 - irbesartan

ChemSpider ChemSpider:YOSHYTLCDANDAN-UHFFFAOYSA-N
DailyMed irbesartan
PubChem SID: 144204986 SID: 170464670 SID: 26719813 SID: 26748950
Wikipedia Irbesartan

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1513



ACToR 138402-11-6
BindingDB 50042235
Brenda 196827
ChEBI 5959
ChemicalBook CB4454663
DrugBank DB01029
DrugCentral 1481
eMolecules 32278040 901986
EPA CompTox Dashboard DTXSID0023169
FDA SRS J0E2756Z7N
Guide to Pharmacology 589 6908
Human Metabolome Database HMDB0015163
IBM Patent System 7549DC2A5ADEC9C99A216A44CD587C2A CD41CEB030B87716F208B66216B92173
KEGG Ligand C07469
LINCS LSM-3338
Mcule MCULE-9617953373
MolPort MolPort-006-167-687 MolPort-003-666-550
NIH Clinical Collection SAM001246548
Nikkaji J549.417F
PharmGKB PA450084
PubChem 3749
PubChem: Drugs of the Future 12014641
PubChem: Thomson Pharma 14905264 14758693
Selleck Irbesartan(Avapro)
SureChEMBL SCHEMBL4246
ZINC ZINC000003872931

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/YOSHYTLCDANDAN-UHFFFAOYSA-N spacer
spacer